well thanks for that so let's divide this into three segments first what is the deal so they are acquiring 50% stake in Sterling biotech from perfect day now this acquisition will lead to Sterling biotech becoming a 50/50 joint venture between zidus life sciences and perfect day with equal representation on the board the newly formed JV aims to establish a manufacturing facility dedicated to uh producing fermented animal free products for Global markets and the cost of acquisition that zidus is doing is around at at around 550 CR now given the new objective of the entity to produce animal free uh protein uh products the company states that a a strategic view of the existing business will be undertaken this means that there may be a they may divest a part of the existing business now note that Sterling biotech's current business includes gelatines and apis and their FY 24 Revenue stands at around 450 CR and uh from fy21 to FY 24 theyve grown at a c gr of around 10% uh namura has rated a neutral rating for this t with Target price of around 1,000 stating the same reasons as I said now the other trigger that is leading to this pressure in the stock pric is their new competition impact so tea has launched a generic version of a product which is used to treat a certain bble disease and zidas over the last year have enjoyed the benefit uh a practical exclusive in absence of any competition and the product seems to have contributed around 140 to1 160 million us of sales in fy4 with the launch of this tavas gener a city believes that the sales of the product may fall 40 to 50% from the current level and as the competition in the product has been delayed by more than 4 years the street seems to be unaware of the concentration risk and their impact may be seen in the valuation so these are the two reasons we are seeing uh pressure on the stock all right thanks for that V well that was the Roundup on why zidus life science is in pressure today uh but with that we'll take it across to our guest for today Vin binar head of head of research from ventur Ventura Securities and Rajesh palia senior vice president Technical and derivative research from access Securities joining hello and welcome to ask profit V let me take it to you the street is not excited about the new acquisition that zidus life science has made what are your views on it how is it looking fundamentally I think uh you know we would like to tell more deeper into the strategy of the company before commenting on the JV uh you know the acquisition vit fair point but just with regard to where we are currently and all the limited information we have and just where valuations are at where zidus life is concerned uh is there a view that you may have no I think the zidus valuations is fairly priced and uh we would like to see more comment come in as I said before making any kind of statement on this acquisition all right Rajesh I'll come to you on this one how is zidus Live Science looking to you on charts so after uh today's gap down uh stock NOW slipped below to its uh 20day 50-day moving average and stock uh has broken down its ups sloping trend line on the downside so looking at the near-term short-term structure we believe that you know some more weakness we could see in the stock prices uh possible downside uh we may see towards 1,70 to 1050 that's the Lower Side the level where we can see G like signs to you know slip further so until the stock not crosses above 11 80 kind of Zone I think we may see further more Supply to there in the stock prices so I think one should wait uh for this supply pressure to settle down maybe around 1,50 1,60 again we can review this stop